CEL — Celadon Pharmaceuticals Cashflow Statement
0.000.00%
- £4.47m
- £9.26m
- £0.08m
Annual cashflow statement for Celadon Pharmaceuticals, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 August 31st | 2020 August 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 16 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -0.206 | -0.187 | -0.722 | -17.4 | -7.26 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | — | — | — | 11.5 | 0.929 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.032 | 0.027 | -1.99 | -0.648 | -0.148 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Payable / Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -0.174 | -0.16 | -2.71 | -6.1 | -5.97 |
Capital Expenditures | — | — | — | -2.09 | -0.341 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | 3.48 | 0 |
Sale of Business | |||||
Purchase of Investments | |||||
Cash from Investing Activities | — | — | — | 1.39 | -0.341 |
Financing Cash Flow Items | -0.308 | 0 | — | -0.024 | 0.032 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 5.82 | 0 | 1.68 | 5.95 | 2.51 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 5.65 | -0.16 | -1.03 | 1.24 | -3.8 |